AKBA
Price
$3.01
Change
-$0.78 (-20.58%)
Updated
Aug 7 closing price
Capitalization
790.53M
90 days until earnings call
CLRPF
Price
$2.85
Change
-$0.32 (-10.09%)
Updated
Aug 7 closing price
Capitalization
1.05B
Interact to see
Advertisement

AKBA vs CLRPF

Header iconAKBA vs CLRPF Comparison
Open Charts AKBA vs CLRPFBanner chart's image
Akebia Therapeutics
Price$3.01
Change-$0.78 (-20.58%)
Volume$14.79M
Capitalization790.53M
Clarity Pharmaceuticals
Price$2.85
Change-$0.32 (-10.09%)
Volume$6.87K
Capitalization1.05B
AKBA vs CLRPF Comparison Chart in %
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. CLRPF commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a Buy and CLRPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (AKBA: $3.01 vs. CLRPF: $2.85)
Brand notoriety: AKBA and CLRPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 327% vs. CLRPF: 89%
Market capitalization -- AKBA: $790.53M vs. CLRPF: $1.05B
AKBA [@Biotechnology] is valued at $790.53M. CLRPF’s [@Biotechnology] market capitalization is $1.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • CLRPF’s FA Score: 0 green, 5 red.
According to our system of comparison, both AKBA and CLRPF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 5 TA indicator(s) are bullish while CLRPF’s TA Score has 3 bullish TA indicator(s).

  • AKBA’s TA Score: 5 bullish, 5 bearish.
  • CLRPF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both AKBA and CLRPF are a good buy in the short-term.

Price Growth

AKBA (@Biotechnology) experienced а -18.32% price change this week, while CLRPF (@Biotechnology) price change was +0.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

AKBA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLRPF($1.05B) has a higher market cap than AKBA($791M). AKBA YTD gains are higher at: 58.421 vs. CLRPF (5.360). AKBA has higher annual earnings (EBITDA): 6.59M vs. CLRPF (-66.98M).
AKBACLRPFAKBA / CLRPF
Capitalization791M1.05B75%
EBITDA6.59M-66.98M-10%
Gain YTD58.4215.3601,090%
P/E RatioN/AN/A-
Revenue185MN/A-
Total Cash113MN/A-
Total Debt54.1MN/A-
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
58
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBACLRPF
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
N/A
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
86%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 15 days ago
85%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
68%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CLRPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFQDX6.930.06
+0.87%
Janus Henderson Global Equity Income D
DCLVX18.92N/A
N/A
Dunham Large Cap Value C
IUAEX28.07N/A
N/A
JPMorgan International Focus A
EMQAX9.03N/A
N/A
Ashmore Emerging Markets Active Eq A
ARALX15.25N/A
N/A
Aristotle Core Eq A

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
-20.48%
XERS - AKBA
39%
Loosely correlated
+20.22%
IPSC - AKBA
38%
Loosely correlated
-2.43%
SYRE - AKBA
37%
Loosely correlated
-4.51%
FENC - AKBA
36%
Loosely correlated
-1.10%
RXRX - AKBA
36%
Loosely correlated
-1.28%
More

CLRPF and

Correlation & Price change

A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRPF
1D Price
Change %
CLRPF100%
-10.09%
SBHMY - CLRPF
24%
Poorly correlated
N/A
BOLD - CLRPF
23%
Poorly correlated
-3.39%
AKBA - CLRPF
21%
Poorly correlated
-20.48%
DOSEF - CLRPF
12%
Poorly correlated
N/A
ACUT - CLRPF
9%
Poorly correlated
+4.37%
More